China Consults on Adding Biotech Technologies to Export Restriction Catalogue
MOFCOM and MOST jointly proposed October additions to China's Catalogue of Technologies Prohibited or Restricted from Export, signalling tighter outbound controls on biotech know-how and affecting licensing and M&A diligence.
China's Ministry of Commerce and Ministry of Science and Technology issued a joint announcement consulting on additions to the Catalogue of Technologies Prohibited or Restricted from Export, with the October 16 batch covering biotechnology-related items. The article describes a consultation-stage proposal, not a final rule, and the specific technology descriptions and scope are not detailed in the source material available here.
Why sophisticated counsel should care: China has been steadily narrowing what technical data and know-how may lawfully leave the country. For clients in life sciences the exposure is threefold — outbound transfer of platform technology or process data to overseas affiliates, partners or CDMOs; licensing of China-sourced technology to foreign licensees, including downstream sublicensing; and valuation and risk allocation in acquisitions of China-based biotech targets, where a catalogue listing can impair an acquirer's ability to commercialise or integrate assets after closing. Change-of-control provisions, closing conditions and export-compliance representations all become more consequential.
Concrete actions: map which of the client's China-origin technologies and data flows intersect the proposed categories; refresh export-control and technology-transfer covenants and closing conditions in pending transactions; and watch for the final catalogue notice, which typically follows the consultation window and sets an effective date. Whether the final scope matches the reported summary is unconfirmed.